Press ReleaseFeb | 6 | 2017
A drug once used to treat diabetes may be of big benefit to skin cancer patients. The treatment of choice for Type 2 diabetes prior to the introduction of metformin, phenformin was taken off the market in 1978 due to concerns about toxicity – it heightened the risk of a fatal buildup of lactate in the body (lactic acidosis). However, phenformin has shown promise as an anti-melanoma therapy where metformin has failed.
Researchers from Memorial Sloan Kettering Cancer Center have filed a request with the FDA to bring back the drug phenformin as a therapeutic for melanoma and are teaming up with researchers from Weill Cornell Medicine and Massachusetts General Hospital to conduct the first clinical trials.